Article

Beta-adrenergic blocking drugs in breast cancer: A perspective review

Department of Pharmacology & Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland.
rapeutic Advances in Medical Oncology, The (Impact Factor: 2.83). 05/2012; 4(3):113-25. DOI: 10.1177/1758834012439738
Source: PubMed

ABSTRACT

The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.

Download full-text

Full-text

Available from: Linda Sharp
  • Source
    • "These findings led to pharmacoepidemiological studies investigating the association between the use of b-adrenergic blocking agents and disease progression in several cancers. Especially in breast cancer, a reduced risk of metastasis development and breast-cancer specific mortality has been described [9]. Phase II clinical trials assessing the safety and efficacy of b-blockers in colorectal and ovarian cancers are underway (NCT00888797, NCT01308944). "

    Full-text · Article · Apr 2014 · British Journal of Dermatology
  • Source
    • "These findings led to pharmacoepidemiological studies investigating the association between the use of b-adrenergic blocking agents and disease progression in several cancers. Especially in breast cancer, a reduced risk of metastasis development and breast-cancer specific mortality has been described [9]. Phase II clinical trials assessing the safety and efficacy of b-blockers in colorectal and ovarian cancers are underway (NCT00888797, NCT01308944). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Results from preclinical and observational studies suggest that β-adrenoreceptor inhibition might influence disease progression of melanoma. Patients ⩾18years with cutaneous melanoma (Breslow thickness >1mm) registered in the Eindhoven Cancer Registry between January 1, 1998 and December 31, 2010, who were also registered with PHARMO record linkage system (RLS), were eligible. Randomly selected patients using β-blockers from PHARMO record linkage system (RLS) matched on age and gender served as a control cohort. Adjusted time-dependent and time-fixed Cox proportional hazard models were employed to estimate the hazard ratio of all-cause mortality. Five-year relative survival rates for all-cause mortality were calculated to estimate disease specific survival. 203 of 709 eligible patients used β-blockers after melanoma diagnosis. The use of β-blockers was not associated with the risk of dying (adjusted hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.55-1.24). Neither duration of exposure nor β-blocker dosage showed significant influence on survival. Five-year relative survival for β-blocker users was lower than in non-users amongst melanoma patients (80.9% and 83.7%, respectively) but higher among the β-blocker control group compared to the general population (101.4%). Our results do not show a statistically significant impact of β-blocker exposure on overall survival of melanoma patients, regardless of the timing, duration or dosage of β-blocker use.
    Full-text · Article · Aug 2013 · European journal of cancer (Oxford, England: 1990)
  • Source
    • "Epidemiological studies have suggested the influence of host factors in both survival and the recurrence of breast cancer, including psychological factors such as depression and chronic stress [1, 2]. The effects are mediated through hormonal and inflammatory pathways and have been found to influence breast cancer progression, angiogenesis and metastasis [3]. Recent studies have showed the importance of the sympathetic nervous system and neuroendocrine regulation in breast cancer [4–6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent preclinical studies have associated beta-adrenergic receptor (β-AR) signaling with breast cancer pathways such as progression and metastasis. These findings have been supported by clinical and epidemiological studies which examined the effect of beta-blocker therapy on breast cancer metastasis, recurrence and mortality. Results from these studies have provided initial evidence for the inhibition of cell migration in breast cancer by beta-blockers and have introduced the beta-adrenergic receptor pathways as a target for therapy. This paper analyzes gene expression profiles in breast cancer patients, utilising Artificial Neural Networks (ANNs) to identify molecular signatures corresponding to possible disease management pathways and biomarker treatment strategies associated with beta-2-adrenergic receptor (ADRB2) cell signaling. The adrenergic receptor relationship to cancer is investigated in order to validate the results of recent studies that suggest the use of beta-blockers for breast cancer therapy. A panel of genes is identified which has previously been reported to play an important role in cancer and also to be involved in the beta-adrenergic receptor signaling.
    Full-text · Article · Mar 2013 · Computational and Structural Biotechnology Journal
Show more